Normal pregnancy is characterized by systemic activation of the complement system

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 17, Issue 4, 2005, Pages 239-245

  Richani, Karina ^a,b   Soto, Eleazar ^a,b   Romero, Roberto ^a,d   Espinoza, Jimmy ^a,b   Chaiworapongsa, Tinnakorn ^a,b   Nien, Jyh Kae ^a   Edwin, Samuel ^a   Kim, Yeon Mee ^a,b   Hong, Joon Seok ^a   Mazor, Moshe ^c  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d HUTZEL HOSPITAL   (United States)

Author keywords

Anaphylatoxins; C3a; C4a; C5a; Complement system; Innate immunity; Pregnancy

Indexed keywords

ANAPHYLATOXIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; COMPLEMENT SYSTEM; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; IMMUNOASSAY; INNATE IMMUNITY; NORMAL HUMAN; PREGNANCY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANAPHYLATOXINS; COMPLEMENT SYSTEM PROTEINS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNITY, NATURAL; PREGNANCY;

EID: 22244454105     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1080/14767050500072722     Document Type: Article

References (61)

1. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004;5:981-986.
2. Kim AH, Dimitriou ID, Holland MC, et al. Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses. J Immunol 2004;173:2524-2529.
3. Schumacher WA, Fantone JC, Kunkel SE, et al. The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo. Agents Actions 1991;34:345-349.
4. Cochrane CG, Muller-Eberhard HJ. The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med 1968;127:371-386.
5. Gorski JP, Hugli TE, Muller-Eberhard HJ. C4a: the third anaphylatoxin of the human complement system. Proc Natl Acad Sci USA 1979;76:5299-302.
6. Bokisch VA, Muller-Eberhard HJ. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest 1970;49:2427-2436.
7. Chenoweth DE, Hugli TE. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1978;75:3943-3947.
8. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004;4:133-42.
9. Ahmed AE, Peter JB. Clinical utility of complement assessment. Clin Diagn Lab Immunol 1995;2:509-17.
10. Bengtson A, Heideman M. Anaphylatoxin formation in sepsis. Arch Surg 1988;123:645-649.
11. Nakae H, Endo S, Inada K, et al. Chronological changes in the complement system in sepsis. Surg Today 1996;26:225-229.
12. Humbles AA, Lu B, Nilsson CA, et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000;406:998-1001.
13. Langlois PF, Gawryl MS. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis 1988;70:95-105.
14. Wang Y, Rollins SA, Madri JA, et al. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995;92:8955-8959.
15. Moxley G, Ruddy S. Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 1985;28:1089-1095.
16. Wild G, Watkins J, Ward AM, et al. C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus. Clin Exp Immunol 1990;80:167-170.
17. Tsuji RF, Kikuchi M, Askenase PW. Possible involvement of C5/C5a in the efferent and elicitation phases of contact sensitivity. J Immunol 1996;156:4444-4450.
18. Xu C, Mao D, Holers VM, et al. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 2000;287:498-501.
19. Girardi G, Herman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112:1644-1654.
20. Girardi G, Salmon JB. The role of complement in pregnancy and fetal loss. Autoimmunity 2003;36:19-26.
21. McCormick JN, Faulk WP, Fox H, et al. Immunohistological and elution studies of the human placenta. J Exp Med 1971;133:1-18.
22. Sinha D, Wells M, Faulk WP. Immunological studies of human placentae: complement components in pre-eclamptic chorionic villi. Clin Exp Immunol 1984;56:175-184.
23. Tedesco F, Narchi G, Radillo O, et al. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol 1993;151:1562-1570.
24. Sacks G, Sargent I, Redman C. An innate view of human pregnancy. Immunol Today 1999;20:114-118.
25. Efrati P, Presentey B, Margalith M, et al. Leukocytes of normal pregnant women. Obstet Gynecol 1964;23:429-432.
26. Naccasha N, Gervasi MT, Chaiworapongsa T, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in normal pregnancy and maternal infection. Am J Obstet Gynecol 2001;185:1118-1123.
27. Sacks GP, Studena K, Sargent K, et al. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998;179:80-86.
28. Comeglio P, Fedi S, Liotta AA, et al. Blood clotting activation during normal pregnancy. Thromb Res 1996;84:199-202.
29. Stirling Y, Woolf L, North WR, et al. Haemostasis in normal pregnancy. Thromb Haemost 1984;52:176-182.
30. Lin H, Mosmann TR, Guilbert L, et al. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol 1993;151:4562-4573.
31. Marzi M, Vigano A, Trabattoni D, et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol 1996;106:127-133.
32. Baines MG, Millar KG, Mills P. Studies of complement levels in normal human pregnancy. Obstet Gynecol 1974;43:806-810.
33. Hopkinson ND, Powell RJ. Classical complement activation induced by pregnancy: implications for management of connective tissue diseases. J Clin Pathol 1992;45:66-67.
34. Kitzmiller JL, Stoneburner L, Yelenosky PF, et al. Serum complement in normal pregnancy and pre-eclampsia. Am J Obstet Gynecol 1973;117:312-315.
35. Levy DL, Arquembourg PC. Maternal and cord blood complement activity: relationship to premature rupture of the membranes. Am J Obstet Gynecol 1981;139:38-40.
36. Holmes CH, Simpson KL, Okada H, et al. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol 1992;22:1579-1585.
37. Hsi BL, Hunt JS, Atkinson JP. Differential expression of complement regulatory proteins on subpopulations of human trophoblast cells. J Reprod Immunol 1991;19:209-223.
38. Buyon JP, Cronstein BN, Morris M, et al. Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia. Am J Med 1986;81:194-200.
39. Massobrio M, Benedetto C, Bertini E, et al. Immune complexes in preeclampsia and normal pregnancy. Am J Obstet Gynecol 1985;152:578-583.
40. Mellembakken JR, Hogasen K, Mollnes TE, et al. Increased systemic activation of neutrophils but not complement in preeclampsia. Obstet Gynecol 2001;97:371-374.
41. Johnson U, Gustavii B. Complement components in normal pregnancy. Acta Pathol Microbiol Immunol Scand [C] 1987;95:97-99.
42. Haeger M, Unander M, Norder-Hansson B, et al. Complement, neutrophil, and macrophage activation in women with severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 1992;79:19-26.
43. Hasty LA, Lambris JD, Lessey BA, et al. Hormonal regulation of complement components and receptors throughout the menstrual cycle. Am J Obstet Gynecol 1994;170:168-175.
44. Sundstrom SA, Komm BS, Ponce-de-Leon H, et al. Estrogen regulation of tissue-specific expression of complement C3. J Biol Chem 1989;264:16941-16947.
45. Cohen AJ, Laskin C, Tarlo S. C1 esterase inhibitor in pregnancy. J Allergy Clin Immunol 1992;90:412-413.
46. Halbmayer WM, Hopmeier P, Mannhalter C, et al. C1-esterase inhibitor in uncomplicated pregnancy and mild and moderate preeclampsia. Thromb Haemost 1991;65:134-138.
47. Ogston D, Walker J, Campbell DM. C1 inactivator level in pregnancy. Thromb Res 1981;23:453-455.
48. Imrie HJ, McGonigle TP, Liu DT, et al. Reduction in erythrocyte complement receptor 1 (CR1, CD35) and decay accelerating factor (DAF, CD55) during normal pregnancy. J Reprod Immunol 1996;31:221-227.
49. Mollnes TE, Brekke OL, Fung M, et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002;100:1869-1877.
50. Sacks T, Moldow CF, Craddock PR, et al. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J Clin Invest 1978;61:1161-2267.
51. Goldstein IM, Roos D, Kaplan HB, et al. Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis. J Clin Invest 1975;56:1155-1163.
52. Shin HS, Snyderman R, Friedman E, et al. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science 1968;162:361-363.
53. Perianayagam MC, Balakrishnan VS, King AJ, et al. C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway. Kidney Int 2002;61:456-463.
54. von Dadelszen P, Watson RW, Noorwali F, et al. Maternal neutrophil apoptosis in normal pregnancy, preeclampsia, and normotensive intrauterine growth restriction. Am J Obstet Gynecol 1999;181:408-414.
55. Huber-Lang M, Younkin EM, Sarma JV, et al. Generation of C5a by phagocytic cells. Am J Pathol 2002;161:1849-1859.
56. Vogt W. Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes. Immunobiology 1996;195:334-346.
57. Ward PA, Hill JH. C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol 1970;104:535-543.
58. Vogt W, Damerau B, von Z, I, et al. Non-enzymic activation of the fifth component of human complement, by oxygen radicals. Some properties of the activation product, C5b-like C5. Mol Immunol 1989;26:1133-1142.
59. Vogt W. Cleavage of the fifth component of complement and generation of a functionally active C5b6-like complex by human leukocyte elastase. Immunobiology 2000;201:470-477.
60. Stabile I, Nicolaides KH, Bach A, et al. Complement factors in fetal and maternal blood and amniotic fluid during the second trimester of normal pregnancy. Br J Obstet Gynaecol 1988;95:281-285.
61. Kovar IZ, Riches PG. C3 and C4 complement components and acute phase proteins in late pregnancy and parturition. J Clin Pathol 1988;41:650-652.